Navigation Links
DURECT Reports Data From European Phase IIb Shoulder Study of POSIDUR™ (SABER™-Bupivacaine) and Amendment of the Nycomed Agreement
Date:2/9/2011

g candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.

DURECT Forward-Looking Statement

The statements in this press release regarding the potential uses and benefits of POSIDUR and our and our partners intended activities relating to POSIDUR, including our expectation of completing enrollment of the U.S. Phase III program in the first half of 2011 and the potential for Nycomed to continue funding development activities for POSIDUR are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements.  Potential risks and uncertainties include, but are not limited to, our ability to enroll the BESST trial in a timely basis, our and Hospira's ability to conduct and complete on-going clinical trials or to design and enroll additional clinical trials, if any, required for regulatory approval, failure of such clinical trials to produce intended results, Nycomed's evaluation of the results of the BESST trial and their decision whether to continue development and funding of POSIDUR, which is in their sole discretion, possible adverse events associated with the use of POSIDUR, delays and costs due to additional work or other requirements imposed by regulatory agencies for continued development, approval or sale of POSIDUR, our ability to complete the design, development, and manufacturing process development of POSIDUR, and to manufacture, commercialize and obtain marketplace acceptance of POSIDUR, and avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund our growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q filed on November 4, 2010 under the heading "Risk Factors.


'/>"/>
SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. DURECT Announces Positive ELADUR(TM) Phase IIa Study Results
2. ELADUR(TM) Development Update: DURECT Receives Orphan Drug Designation for Bupivacaine for Post-Herpetic Neuralgia
3. DURECT Reports Positive Phase IIb Data from TRANSDU(TM)-Sufentanil Clinical Program
4. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
5. DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference
6. DURECT Corporation Invites You to Join Its Fourth Quarter 2009 Earnings Conference Call
7. DURECT and Nycomed Amend POSIDUR(TM) License Agreement to Separate Funding and Control of U.S. and E.U. Clinical Programs and to Expand Territory
8. DURECT Corporation Announces Fourth Quarter and Year End 2009 Financial Results
9. DURECT to Present at the Cowen and Company Healthcare Conference
10. DURECT to Present at the Barclays Capital Global Healthcare Conference
11. DURECT Corporation Invites You to Join Its First Quarter 2010 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... is being recalled after Health Canada tests confirmed it ... health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health ... recalling the product from retail stores across ... building purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... 24, 2014  Commonwealth Cornerstone Group (CCG) today announced the ... on Tuesday to help fund the expansion and consolidation of ... Sharon . PHN is the ... . It is the largest employer in ... people on staff. Currently, PHN Sharon offers scattered ...
(Date:12/24/2014)... N.J. , Dec. 24, 2014 ... a late-stage biopharmaceutical company developing products that address ... oncology and biodefense, announced today that on December ... public offering. The Company raised approximately ... and intends to use the net proceeds from ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 2Commonwealth Cornerstone Group Announces $8 Million in Tax Credits to Expand and Consolidate Healthcare Services in Sharon 3Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... ARBOR, Mich., May 14, 2012  Synthetic Biologics, Inc. (NYSE ... DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses, ... Senior Vice President of Clinical & Regulatory Affairs. In ... design and implementation of all aspects of clinical development, ...
... 11, 2012 Dynatronics Corporation (NASDAQ: DYNT ) ... months ended March 31, 2012 during the morning of Tuesday, ... conference call for investors later that day at 3:30 p.m. ... month periods.  Those interested in participating should call (800) 676-3536. ...
Cached Medicine Technology:Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 2Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs 3
(Date:12/26/2014)... WA (PRWEB) December 26, 2014 “Many ... deal with personal injury claim issues and phone calls ... recently released an article featuring their free eBook ... exceptionally helpful eBook on pedestrian and bicycle auto accident ... attorney is fully capable of professionally handling their case ...
(Date:12/25/2014)... December 26, 2014 The microscopy ... of 7.2% to reach $5,756.0 million by 2019. ... microscopy market. The electron microscopes product segment is ... forecast period. , Rising focus on nanotechnology, technological ... of the microscopy market. , Get Full Copy ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... Recently, BellasDress has launched ... wedding dresses. BellasDress has chosen their best-selling lace wedding ... for the holiday season. , Now, BellasDress.com features ... gowns here at discount prices. The business hopes everyone ... website. , “All our elegant products are ...
(Date:12/25/2014)... By Dennis Thompson ... -- Very sick children with complex chronic illnesses can receive ... a "medical home," with easy access to a team of ... were less likely to become seriously ill and need either ... received treatment at an enhanced medical home clinic at the ...
Breaking Medicine News(10 mins):Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... teens, TOPEKA, Kan., Oct. 19 Attorney General ... with new 30-second,radio public service announcements set to air ... coincide with the busy fall season and will,air more ... November. "With teens heading off to parties, dances ...
... recent study by Celent, a leading,financial services technology research ... of eight firms leading the way as a change ... transactions. Celent,s Healthcare Banking research service based its ... Mellon,s Treasury Services division to,apply its scale, technology and ...
... SPRINGS, Colo., Oct. 19 ,Spectranetics Corporation (Nasdaq: ... 2007 third quarter financial results prior to market ... host an,investment-community conference call beginning at 9:00 a.m. ... 31 to discuss those results,and to answer questions. ...
... SANTA ANA, Calif., Oct. 19 Today, Integrated,Healthcare ... owner of,four Orange County hospitals, announced that effective ... of all of its debt instruments. The,Company said ... with Medical,Capital Corporation and affiliates of Anaheim, California, ...
... Company,(Nasdaq: PRGO ; TASE) today announced that it ... on Thursday, November 1, 2007 at,approximately 8:00 a.m. (ET). ... (ET) hosted by Joseph C. Papa, Perrigo,s President and ... live via webcast to interested,parties on the Perrigo website ...
... AAFP President Michael Fleming, MD will serve as Digital,s Medical ... Director ... Healthcare, a Wake,Forest, NC company specializing in retinal risk assessment for ... for Primary Care. In his new role, Dr. Fleming will,provide Digital ...
Cached Medicine News:Health News:Morrison Takes Aim at Underage Drinking in New Radio Campaign 2Health News:The Bank of New York Mellon Recognized as Change Agent Shaping the Direction of Healthcare Transaction Processing 2Health News:Spectranetics to Hold 2007 Third Quarter Financial Results Conference Call on October 31 2Health News:IHHI Announces Completion of Re-Financing 2Health News:Digital Healthcare Announces Dr. Michael Fleming Joins Executive Team as Medical Director 2
... drape sheets with a low-profile, roomy ... the operative site during arthroscopic surgery. ... ports for drainage. , ,The ... a standard pack, or in custom ...
... includes bed side and near patient testing ... This growth has posed unique problems for ... and quality responsibility to decentralized areas focused ... Compounding the problem is the reality of ...
... First Consolidated Workstation to Automate Deparaffinization, ... Staining,Now you can perform deparaffinization, pretreatment, ... routine slide washing with a single ... preprogrammed Vysis protocols for fluorescence in ...
... sample preparation platform is an efficient system ... from patient samples using novel magnetic particle ... sample preparation and is cabable of processing ... a 1 ml sample volume., ,This platform ...
Medicine Products: